Impact of Severe Tricuspid Regurgitation Correction on Gut Microbiota and Gastrointestinal Function

Launched by FRANCESCO MAISANO · Mar 24, 2025

Keywords

ClinConnect Summary

No description provided

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Adult patients, able to sign the Informed Consent Form, admitted to OSR Heart Valve Center with TR ≥ severe treated with T-TEER.
• Exclusion Criteria:
• • Concomitant ≥ severe MR. Such patients may be treated with M-TEER and be re-evaluated after 3 months: if TR is ≥ severe and MR is ≤ moderate the patient may then be enrolled.
• • Surgical candidates
• • Recent \< 6 months cardiac coronary or structural procedure
• • CAD requiring intervention
• • other valvular disease \> moderate
• • Treatment with transcatheter tricuspid replacement
• • Age \<18 years
• • Inability or unwillingness to sign informed consent
• • Kidney dialysis
• • Acute infection
• • Inflammatory bowel diseases
• • Gastrointestinal diseases
• • Previous gastrointestinal surgery
• • Active cancer
• • Active autoimmune or inflammatory diseases
• • Treatments with antibiotics or probiotics within one month
• • Emergency procedures
• • Patients enrolled in interventional studies that may confound study results